Nektar Therapeutics
Nektar Therapeutics, a leading biopharmaceutical company headquartered in the United States, focuses on innovative drug development to address unmet medical needs. Founded in 1990, Nektar has made significant strides in the industry, particularly in the fields of oncology, immunology, and pain management.
The company is renowned for its proprietary drug delivery technologies, which enhance the efficacy and safety of therapeutic agents. Nektar's core products, including its advanced therapies for cancer and chronic pain, stand out due to their unique mechanisms of action and patient-centric design.
With a strong market position, Nektar Therapeutics has achieved notable milestones, including strategic partnerships and a robust pipeline of clinical candidates, solidifying its reputation as a pioneer in the biopharmaceutical landscape.
-18 vs industry average
Nektar Therapeutics’s score of 20 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Nektar Therapeutics?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Nektar Therapeutics yet.
Nektar Therapeutics's reported carbon emissions
Nektar Therapeutics, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company.
As of now, Nektar Therapeutics has not established any science-based targets or commitments to reduce emissions, nor does it inherit any emissions data from a parent company. This lack of publicly available information suggests that the company may still be in the early stages of developing its climate strategy and emissions reporting framework.
In the broader context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. Nektar Therapeutics may benefit from aligning with industry standards and practices to enhance its environmental commitments in the future.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Nektar Therapeutics’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Nektar Therapeutics yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Nektar Therapeutics
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project